全球醫藥CDMO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計醫藥CDMO市場將從2025年的1,821.5億美元成長到2034年的3,474.8億美元，2026年至2034年的複合年成長率為7.44%。

隨著製藥公司擴大將藥物研發和生產流程外包，全球合約研發生產機構（CDMO）市場正經歷強勁成長。 CDMO提供藥物製劑、臨床試驗用藥生產和大規模生產等專業服務，使製藥公司能夠專注於研發和商業化。

市場的主要促進因素之一是藥物研發日益複雜以及生產設施建設成本不斷攀升。製藥和生物技術公司依賴合約研發生產機構（CDMO）來降低營運成本並縮短產品研發週期。此外，生物製藥和個人化醫療的成長也推動了對專業化生產能力的需求。

隨著全球藥品研發管線的不斷擴展，藥品合約研發生產力機構（CDMO）市場也預計將隨之成長。生物技術研發投入的增加以及創新治療方法的開發將進一步推動對外包服務的需求。憑藉製造技術的進步和監管方面的專業知識，CDMO將在未來的藥品生產中發揮至關重要的作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球醫藥CDMO市場：依產品分類

• 市場分析、洞察與預測
• API
• 製藥

第5章 全球醫藥CDMO市場：依工作流程分類

• 市場分析、洞察與預測
• 臨床階段
• 商業的

第6章 全球醫藥CDMO市場：依應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 低分子化合物
• 生物製劑
• 感染疾病
• 神經系統疾病
• 心血管疾病
• 代謝性疾病
• 自體免疫疾病
• 呼吸系統疾病
• 眼科
• 消化系統疾病
• 荷爾蒙失調
• 血液疾病
• 其他

第7章 全球醫藥CDMO市場：依最終用途分類

• 市場分析、洞察與預測
• 小規模製藥公司
• 中型製藥公司
• 大型製藥企業

第8章 全球醫藥CDMO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza
  • Thermo Fisher Scientific Inc
  • Recipharm AB
  • Laboratory Corporation Of America Holdings（LabCorp）
  • Catalent Inc
  • WuXi AppTec Inc
  • Samsung Biologics
  • Piramal Pharma Solutions
  • Siegfried Holding AG
  • CordenPharma International
  • Cambrex Corporation
  • Bushu Pharmaceuticals Ltd
  • Nipro Corporation

The Pharmaceutical CDMO Market size is expected to reach USD 347.48 Billion in 2034 from USD 182.15 Billion (2025) growing at a CAGR of 7.44% during 2026-2034.

The Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is experiencing strong growth as pharmaceutical companies increasingly outsource drug development and manufacturing processes. CDMOs provide specialized services such as drug formulation, clinical trial manufacturing, and large-scale production, allowing pharmaceutical companies to focus on research and commercialization.

One of the primary drivers of the market is the rising complexity of drug development and the increasing cost of establishing manufacturing facilities. Pharmaceutical and biotechnology companies rely on CDMOs to reduce operational expenses and accelerate product development timelines. Additionally, the growth of biologics and personalized medicines has increased demand for specialized manufacturing capabilities.

Looking ahead, the pharmaceutical CDMO market is expected to expand as the global pharmaceutical pipeline continues to grow. Increasing investment in biotechnology research and the development of innovative therapies will further drive demand for outsourcing services. With advancements in manufacturing technologies and regulatory compliance expertise, CDMOs will play a crucial role in the future of pharmaceutical production.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• API
• Drug Product

By Workflow

• Clinical
• Commercial

By Application

• Oncology
• Small Molecules
• Biologics
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Hormonal Disorders
• Hematological Disorders
• Others

By End-use

• Small Pharmaceutical Companies
• Medium Pharmaceutical Companies
• Large Pharmaceutical Companies

COMPANIES PROFILED

• Lonza, Thermo Fisher Scientific Inc, Recipharm AB, Laboratory Corporation of America Holdings LabCorp, Catalent Inc, WuXi AppTec Inc, Samsung Biologics, Piramal Pharma Solutions, Siegfried Holding AG, CordenPharma International, Cambrex Corporation, Bushu Pharmaceuticals Ltd, Nipro Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PHARMACEUTICAL CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. API Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drug Product Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PHARMACEUTICAL CDMO MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PHARMACEUTICAL CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.11. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.12. Gastrointestinal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.13. Hormonal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.14. Hematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.15. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PHARMACEUTICAL CDMO MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Small Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Medium Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Large Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PHARMACEUTICAL CDMO MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Workflow
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Workflow
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Workflow
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Workflow
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Workflow
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PHARMACEUTICAL CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Lonza
  • 10.2.2 Thermo Fisher Scientific Inc
  • 10.2.3 Recipharm AB
  • 10.2.4 Laboratory Corporation Of America Holdings (LabCorp)
  • 10.2.5 Catalent Inc
  • 10.2.6 WuXi AppTec Inc
  • 10.2.7 Samsung Biologics
  • 10.2.8 Piramal Pharma Solutions
  • 10.2.9 Siegfried Holding AG
  • 10.2.10 CordenPharma International
  • 10.2.11 Cambrex Corporation
  • 10.2.12 Bushu Pharmaceuticals Ltd
  • 10.2.13 Nipro Corporation